Company intelligence / Profile preview
AKSO Biopharmaceutical
Los Angeles, California, United Statesaksobio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AKSO’s lead programs are in late preclinical development. AB001, a first-in-class soluble BCMA decoy receptor targeting APRIL and BAFF, has shown efficacy in mouse models of multiple myeloma and DLBCL with good safety in non-human primates. AB002 is a bi-functional fusion protein that neutralizes PD-L1/PD-L2 and activates NK cells via an IL‑15 agonist; it is being developed for solid tumors through a partnership for Asia-Pacific ex-Japan.
- Therapeutic areas
- OncologyRare DiseasesImmunologyHematologyNephrology
- Modalities
- Fusion proteinBispecific antibodyAntibody-drug conjugateRecombinant fusion proteinAntibody fusion proteins
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Huadong Medicine (for development/commercialization of AB002 in Asia-Pacific ex-Japan)Chime Biologics (CDMO partner for manufacturing support)
Beyond the preview
Go deeper on AKSO Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKSO Biopharmaceutical.